dihexa human clinical trials 2026 International Day 2026: inside First-in-Human trials Dihexa in Clinical Trials: What

Increasing evidence suggests that soluble A oligomers, rather than insoluble plaques, are major contributors to synaptic dysfunction and cognitive decline in AD, although their precise pathogenic role remains under active investigation and debate (Selkoe, 2008

Microglia NLRP3 Inflammasomes activation involving diabetic Neuroinflammation in diabetic mice and BV2 cells

Patient Experience: What to Expect Starting a brain repair protocol is a commitment

Similarly, both groups traveled longer distance in the platform quadrant than the controls did ( P = 0.0467 for the combination group and P = 0.0191 for the standard drug group

This section covers what is known about safety along with theoretical concerns